It increases production significantly, lowers manufacturing costs in a process that is very custom, and means that any other company wanting to compete in the Dendritic arena will have to overcome much more than just an effective Dendritic Vaccine that does not go against the NWBO patent. So a company like Mill Creek NOT ONLY has to come up with the TIME & FUNDS for a Phase 3 trial, they would still not be able to compete with the manufacturing. NWBO has cemented themselves in a very good position to become the LEADER in dendritic cell vaccine technology, meaning, it will be a long time for a competitive Big Pharma will be entering the Dendritic Cell Personalized Vaccine space....
Market Data 
Markets 
AI
